News from Amgen
Stay current with all the latest and breaking news about Amgen, compare headlines and perspectives between news sources on stories happening today. In total, 57 stories have been published about Amgen which Ground News has aggregated in the past 3 months.
Covered Most By
Suggest a source
Looking for a source we don't already have? Suggest one here.Top Amgen News
Latest News Stories
Amgen · New DelhiAmgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly needed new option for patients when chemotherapy stops working.See the Story
Amgen Drug Wins US Approval for Type of Advanced Lung Cancer
100% Center coverage: 1 sources
ObesityViking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has been in the news, owing to updates from its obesity program. The company, with a market cap of about $8 billion, is developing its lead candidate, VK2735, a dual GLP-1/GIP agonist. The candidate is being developed both as a subcutaneous injection and as an oral pill in a mid-stage study and an early-sta…See the Story
Should You Hold Viking Therapeutics in Your Portfolio? - Eli Lilly and Co (NYSE:LLY), Amgen (NASDAQ:AMGN)
100% Center coverage: 1 sources
Amgen · ChicagoAmgen headquarters in Thousand Oaks, California.Adobe Stock When doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician Don Crosslin was an early beneficiary. Crosslin started the drug that July. His tumors shrank, then stabilized.But while the drug has helped keep him alive, its side effects have gradually narrowed the confines of his life, says Cro…See the Story
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge
100% Left coverage: 1 sources
Amgen · Thousand OaksWhen doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician Don Crosslin was an early beneficiary. Crosslin started the drug that July. His tumors shrank, then stabilized.See the Story
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge
100% Center coverage: 1 sources